Department of Gynecological Endocrinology and Reproductive Medicine, Woman's University Hospital of Bern, Effingerstrasse 102, Bern, Switzerland.
Arch Gynecol Obstet. 2010 Jul;282(1):83-8. doi: 10.1007/s00404-009-1308-5. Epub 2009 Dec 6.
To determine the protective effect of gonadotropin-releasing hormone analogs (GnRHa) using several ultrasound and endocrine markers to detect ultrastructural ovarian damage in Hodgkin's lymphoma patients.
Ten patients who had been treated for Hodgkin's lymphoma and had received GnRHa to protect ovarian function were matched with patients at similar age, who had received the same chemotherapy regimens without GnRHa. In addition, ten healthy women at the same age were matched to the study groups to compare ovarian markers. Blood samples were drawn to determine anti-Müllerian hormone, Inhibin B, follicle-stimulating hormone and transvaginal ultrasound scans were performed to determine antral follicle count and ovarian volume. All women were asked about their menstrual cycle pattern.
No difference was found when comparing the ovarian parameters of both study groups. Compared with healthy women, all ovarian parameters in the Hodgkin's lymphoma patients were significantly different.
The results of this study demonstrate ultrastructural ovarian damage in Hodgkin's lymphoma patients irrespective of GnRHa co-treatment. These findings do not support previous studies, showing GnRHa to protect ovarian function.
使用多种超声和内分泌标志物来检测霍奇金淋巴瘤患者的超微结构卵巢损伤，以确定促性腺激素释放激素类似物（GnRHa）的保护作用。
选择 10 例接受 GnRHa 保护卵巢功能的霍奇金淋巴瘤患者作为治疗组，并与年龄相匹配、接受相同化疗方案但未使用 GnRHa 的患者进行配对。此外，还选择了 10 名年龄相匹配的健康女性作为对照组，以比较卵巢标志物。采集血样以测定抗苗勒管激素、抑制素 B、卵泡刺激素，并进行经阴道超声检查以测定窦卵泡计数和卵巢体积。所有女性均被问及月经周期模式。
两组的卵巢参数比较无差异。与健康女性相比，霍奇金淋巴瘤患者的所有卵巢参数均显著不同。
本研究结果表明，霍奇金淋巴瘤患者存在超微结构卵巢损伤，无论是否联合 GnRHa 治疗。这些发现与先前表明 GnRHa 可保护卵巢功能的研究结果不一致。
